Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB.

J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392. [Epub ahead of print]

PMID:
30235087
2.

The Diagnostic Value of MRI Pattern Recognition in Distal Myopathies.

Bugiardini E, Morrow JM, Shah S, Wood CL, Lynch DS, Pitmann AM, Reilly MM, Houlden H, Matthews E, Parton M, Hanna MG, Straub V, Yousry TA.

Front Neurol. 2018 Jun 26;9:456. doi: 10.3389/fneur.2018.00456. eCollection 2018.

3.

Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.

Schuh A, Dreau H, Knight SJL, Ridout K, Mizani T, Vavoulis D, Colling R, Antoniou P, Kvikstad EM, Pentony MM, Hamblin A, Protheroe A, Parton M, Shah KA, Orosz Z, Athanasou N, Hassan B, Flanagan AM, Ahmed A, Winter S, Harris A, Tomlinson I, Popitsch N, Church D, Taylor JC.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002279. doi: 10.1101/mcs.a002279. Print 2018 Apr.

4.

Mobility shift of beta-dystroglycan as a marker of GMPPB gene-related muscular dystrophy.

Sarkozy A, Torelli S, Mein R, Henderson M, Phadke R, Feng L, Sewry C, Ala P, Yau M, Bertoli M, Willis T, Hammans S, Manzur A, Sframeli M, Norwood F, Rakowicz W, Radunovic A, Vaidya SS, Parton M, Walker M, Marino S, Offiah C, Farrugia ME, Mamutse G, Marini-Bettolo C, Wraige E, Beeson D, Lochmüller H, Straub V, Bushby K, Barresi R, Muntoni F.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):762-768. doi: 10.1136/jnnp-2017-316956. Epub 2018 Feb 3.

PMID:
29437916
5.

Atypical periodic paralysis and myalgia: A novel RYR1 phenotype.

Matthews E, Neuwirth C, Jaffer F, Scalco RS, Fialho D, Parton M, Raja Rayan D, Suetterlin K, Sud R, Spiegel R, Mein R, Houlden H, Schaefer A, Healy E, Palace J, Quinlivan R, Treves S, Holton JL, Jungbluth H, Hanna MG.

Neurology. 2018 Jan 30;90(5):e412-e418. doi: 10.1212/WNL.0000000000004894. Epub 2018 Jan 3.

6.

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.

Dodson A, Okonji D, Assersohn L, Rigg A, Sheri A, Turner N, Smith I, Parton M, Dowsett M.

Breast Cancer Res Treat. 2018 Feb;168(1):249-258. doi: 10.1007/s10549-017-4514-z. Epub 2017 Nov 11.

7.

Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy.

Morís G, Wood L, FernáNdez-Torrón R, González Coraspe JA, Turner C, Hilton-Jones D, Norwood F, Willis T, Parton M, Rogers M, Hammans S, Roberts M, Househam E, Williams M, Lochmüller H, Evangelista T.

Muscle Nerve. 2018 Mar;57(3):380-387. doi: 10.1002/mus.25991. Epub 2017 Nov 7.

8.

Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.

Kingston B, Kayhanian H, Brooks C, Cox N, Chaabouni N, Redana S, Kalaitzaki E, Smith I, O'Brien M, Johnston S, Parton M, Noble J, Stanway S, Ring A, Turner N, Okines A.

Breast. 2017 Dec;36:54-59. doi: 10.1016/j.breast.2017.07.015. Epub 2017 Sep 29.

PMID:
28968585
9.

Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.

Okines A, Irfan T, Khabra K, Smith I, O'Brien M, Parton M, Noble J, Stanway S, Somaiah N, Ring A, Johnston S, Turner N.

Breast J. 2018 May;24(3):253-259. doi: 10.1111/tbj.12906. Epub 2017 Aug 22.

PMID:
28833867
10.

Calpainopathy with macrophage-rich, regional inflammatory infiltrates.

Schutz PW, Scalco RS, Barresi R, Houlden H, Parton M, Holton JL.

Neuromuscul Disord. 2017 Aug;27(8):738-741. doi: 10.1016/j.nmd.2017.04.012. Epub 2017 Apr 27.

PMID:
28602176
11.

Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.

Lilleker JB, Rietveld A, Pye SR, Mariampillai K, Benveniste O, Peeters MT, Miller JA, Hanna MG, Machado PM, Parton MJ, Gheorghe KR, Badrising UA, Lundberg IE, Sacconi S, Herbert MK, McHugh NJ, Lecky BR, Brierley C, Hilton-Jones D, Lamb JA, Roberts ME, Cooper RG, Saris CG, Pruijn GJ, Chinoy H, van Engelen BG; all UKMYONET contributors.

Ann Rheum Dis. 2017 May;76(5):862-868. doi: 10.1136/annrheumdis-2016-210282. Epub 2017 Jan 25.

12.

Tubular Aggregates and Cylindrical Spirals Have Distinct Immunohistochemical Signatures.

Brady S, Healy EG, Gang Q, Parton M, Quinlivan R, Jacob S, Curtis E, Al-Sarraj S, Sewry CA, Hanna MG, Houlden H, Beeson D, Holton JL.

J Neuropathol Exp Neurol. 2016 Dec;75(12):1171-1178.

PMID:
27941137
13.

Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis.

Gang Q, Bettencourt C, Machado PM, Brady S, Holton JL, Pittman AM, Hughes D, Healy E, Parton M, Hilton-Jones D, Shieh PB, Needham M, Liang C, Zanoteli E, de Camargo LV, De Paepe B, De Bleecker J, Shaibani A, Ripolone M, Violano R, Moggio M, Barohn RJ, Dimachkie MM, Mora M, Mantegazza R, Zanotti S, Singleton AB, Hanna MG, Houlden H; Muscle Study Group and The International IBM Genetics Consortium.

Neurobiol Aging. 2016 Nov;47:218.e1-218.e9. doi: 10.1016/j.neurobiolaging.2016.07.024. Epub 2016 Aug 8.

14.

Seizure: acute investigation and management.

Devine H, Parton M.

Br J Hosp Med (Lond). 2016 Sep 2;77(9):C134-7. doi: 10.12968/hmed.2016.77.9.C134. No abstract available.

PMID:
27640668
15.

CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies.

Scalco RS, Gardiner AR, Pitceathly RD, Hilton-Jones D, Schapira AH, Turner C, Parton M, Desikan M, Barresi R, Marsh J, Manzur AY, Childs AM, Feng L, Murphy E, Lamont PJ, Ravenscroft G, Wallefeld W, Davis MR, Laing NG, Holton JL, Fialho D, Bushby K, Hanna MG, Phadke R, Jungbluth H, Houlden H, Quinlivan R.

Neuromuscul Disord. 2016 Aug;26(8):504-10. doi: 10.1016/j.nmd.2016.05.006. Epub 2016 May 11.

PMID:
27312022
16.

Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.

Kristeleit H, Parton M, Beresford M, Macpherson IR, Sharma R, Lazarus L, Kelleher M.

Target Oncol. 2016 Oct;11(5):579-591. Review.

17.

Clinical features of the myasthenic syndrome arising from mutations in GMPPB.

Rodríguez Cruz PM, Belaya K, Basiri K, Sedghi M, Farrugia ME, Holton JL, Liu WW, Maxwell S, Petty R, Walls TJ, Kennett R, Pitt M, Sarkozy A, Parton M, Lochmüller H, Muntoni F, Palace J, Beeson D.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):802-9. doi: 10.1136/jnnp-2016-313163. Epub 2016 May 4.

18.

Targeting protein homeostasis in sporadic inclusion body myositis.

Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, Noel J, Wang Y, McVey AL, Pasnoor M, Gallagher P, Statland J, Lu CH, Kalmar B, Brady S, Sethi H, Samandouras G, Parton M, Holton JL, Weston A, Collinson L, Taylor JP, Schiavo G, Hanna MG, Barohn RJ, Dimachkie MM, Greensmith L.

Sci Transl Med. 2016 Mar 23;8(331):331ra41. doi: 10.1126/scitranslmed.aad4583.

19.

USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.

Berger BM, Parton MA, Levin B.

Am J Manag Care. 2016 Feb 1;22(2):e77-81.

20.

Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype.

Jaffer F, Avbersek A, Vavassori R, Fons C, Campistol J, Stagnaro M, De Grandis E, Veneselli E, Rosewich H, Gianotta M, Zucca C, Ragona F, Granata T, Nardocci N, Mikati M, Helseth AR, Boelman C, Minassian BA, Johns S, Garry SI, Scheffer IE, Gourfinkel-An I, Carrilho I, Aylett SE, Parton M, Hanna MG, Houlden H, Neville B, Kurian MA, Novy J, Sander JW, Lambiase PD, Behr ER, Schyns T, Arzimanoglou A, Cross JH, Kaski JP, Sisodiya SM.

Brain. 2015 Oct;138(Pt 10):2859-74. doi: 10.1093/brain/awv243. Epub 2015 Aug 21.

21.

Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.

Belaya K, Rodríguez Cruz PM, Liu WW, Maxwell S, McGowan S, Farrugia ME, Petty R, Walls TJ, Sedghi M, Basiri K, Yue WW, Sarkozy A, Bertoli M, Pitt M, Kennett R, Schaefer A, Bushby K, Parton M, Lochmüller H, Palace J, Muntoni F, Beeson D.

Brain. 2015 Sep;138(Pt 9):2493-504. doi: 10.1093/brain/awv185. Epub 2015 Jun 30.

22.

Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK.

Figueroa-Bonaparte S, Hudson J, Barresi R, Polvikoski T, Williams T, Töpf A, Harris E, Hilton-Jones D, Petty R, Willis TA, Longman C, Dougan CF, Parton MJ, Hanna MG, Quinlivan R, Farrugia ME, Guglieri M, Bushby K, Straub V, Lochmüller H, Evangelista T.

J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):680-1. doi: 10.1136/jnnp-2015-310362. Epub 2015 Jun 23. No abstract available.

23.

Conspiracy theory and cognitive style: a worldview.

Dagnall N, Drinkwater K, Parker A, Denovan A, Parton M.

Front Psychol. 2015 Feb 25;6:206. doi: 10.3389/fpsyg.2015.00206. eCollection 2015.

24.

The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis.

Gang Q, Bettencourt C, Machado PM, Fox Z, Brady S, Healy E, Parton M, Holton JL, Hilton-Jones D, Shieh PB, Zanoteli E, De Paepe B, De Bleecker J, Shaibani A, Ripolone M, Violano R, Moggio M, Barohn RJ, Dimachkie MM, Mora M, Mantegazza R, Zanotti S, Hanna MG, Houlden H; Muscle Study Group and the International IBM Genetics Consortium(#).

Neurobiol Aging. 2015 Apr;36(4):1766.e1-1766.e3. doi: 10.1016/j.neurobiolaging.2014.12.039. Epub 2015 Jan 14.

25.

Ongoing developments in sporadic inclusion body myositis.

Machado PM, Ahmed M, Brady S, Gang Q, Healy E, Morrow JM, Wallace AC, Dewar L, Ramdharry G, Parton M, Holton JL, Houlden H, Greensmith L, Hanna MG.

Curr Rheumatol Rep. 2014 Dec;16(12):477. doi: 10.1007/s11926-014-0477-9. Review.

26.

Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.

Georgieva Z, Parton M.

BMJ Case Rep. 2014 Jan 13;2014. pii: bcr2013202314. doi: 10.1136/bcr-2013-202314.

27.

A practical approach to diagnosing adult onset leukodystrophies.

Ahmed RM, Murphy E, Davagnanam I, Parton M, Schott JM, Mummery CJ, Rohrer JD, Lachmann RH, Houlden H, Fox NC, Chataway J.

J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):770-81. doi: 10.1136/jnnp-2013-305888. Epub 2013 Dec 19. No abstract available.

PMID:
24357685
28.

A multicentre postal survey investigating the contribution of illness perceptions, coping and optimism to quality of life and mood in adults with muscle disease.

Graham CD, Weinman J, Sadjadi R, Chalder T, Petty R, Hanna MG, Turner C, Parton M, Maddison P, Radunovic A, Longman C, Robb Y, Bushby K, Hilton-Jones D, Rose MR.

Clin Rehabil. 2014 May;28(5):508-19. doi: 10.1177/0269215513511340. Epub 2013 Nov 15.

PMID:
24240060
29.

Frequency and circumstances of falls in people with inclusion body myositis: a questionnaire survey to explore falls management and physiotherapy provision.

Hiscock A, Dewar L, Parton M, Machado P, Hanna M, Ramdharry G.

Physiotherapy. 2014 Mar;100(1):61-5. doi: 10.1016/j.physio.2013.06.002. Epub 2013 Aug 15.

PMID:
23954023
30.

Noninvasive detection of HER2 amplification with plasma DNA digital PCR.

Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC.

Clin Cancer Res. 2013 Jun 15;19(12):3276-84. doi: 10.1158/1078-0432.CCR-12-3768. Epub 2013 May 1.

31.

ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation.

Sarkozy A, Hicks D, Hudson J, Laval SH, Barresi R, Hilton-Jones D, Deschauer M, Harris E, Rufibach L, Hwang E, Bashir R, Walter MC, Krause S, van den Bergh P, Illa I, Pénisson-Besnier I, De Waele L, Turnbull D, Guglieri M, Schrank B, Schoser B, Seeger J, Schreiber H, Gläser D, Eagle M, Bailey G, Walters R, Longman C, Norwood F, Winer J, Muntoni F, Hanna M, Roberts M, Bindoff LA, Brierley C, Cooper RG, Cottrell DA, Davies NP, Gibson A, Gorman GS, Hammans S, Jackson AP, Khan A, Lane R, McConville J, McEntagart M, Al-Memar A, Nixon J, Panicker J, Parton M, Petty R, Price CJ, Rakowicz W, Ray P, Schapira AH, Swingler R, Turner C, Wagner KR, Maddison P, Shaw PJ, Straub V, Bushby K, Lochmüller H.

Hum Mutat. 2013 Aug;34(8):1111-8. doi: 10.1002/humu.22342. Epub 2013 Jun 12.

PMID:
23606453
32.

Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials.

Cortese A, Machado P, Morrow J, Dewar L, Hiscock A, Miller A, Brady S, Hilton-Jones D, Parton M, Hanna MG.

Neuromuscul Disord. 2013 May;23(5):404-12. doi: 10.1016/j.nmd.2013.02.010. Epub 2013 Mar 11.

PMID:
23489664
33.

A case of necrotizing myopathy with proximal weakness and cardiomyopathy.

Matthews E, Plotz PH, Portaro S, Parton M, Elliott P, Humbel RL, Holton JL, Keegan BM, Hanna MG.

Neurology. 2012 May 8;78(19):1527-32. doi: 10.1212/WNL.0b013e3182553baa. No abstract available.

PMID:
22565568
34.

Camptocormia: don't forget muscle disease in the movement disorder clinic.

Doherty KM, Silveira-Moriyama L, Giladi N, Bhatia KP, Parton M, Lees AJ.

J Neurol. 2012 Aug;259(8):1752-4. doi: 10.1007/s00415-012-6448-z. Epub 2012 Feb 17. No abstract available.

PMID:
22349871
35.

Clinical and pathological heterogeneity in late-onset partial merosin deficiency.

Rajakulendran S, Parton M, Holton JL, Hanna MG.

Muscle Nerve. 2011 Oct;44(4):590-3. doi: 10.1002/mus.22196.

PMID:
21922472
36.

The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy.

Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M.

Eur J Cancer. 2011 Sep;47(14):2099-106. doi: 10.1016/j.ejca.2011.05.010. Epub 2011 Jun 12.

PMID:
21658935
37.

Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience.

Waddell T, Kotsori A, Constantinidou A, Yousaf N, Ashley S, Parton M, Allen M, Starling N, Papadopoulos P, O'Brien M, Smith I, Johnston S.

Br J Cancer. 2011 May 24;104(11):1675-9. doi: 10.1038/bjc.2011.138. Epub 2011 Apr 26.

38.

Is capecitabine efficacious in triple negative metastatic breast cancer?

Kotsori AA, Dolly S, Sheri A, Parton M, Shaunak N, Ashley S, Walsh G, Johnston S, Smith IE.

Oncology. 2010;79(5-6):331-6. doi: 10.1159/000323175. Epub 2011 Mar 23.

PMID:
21430400
39.

A novel MYH7 mutation occurring independently in French and Norwegian Laing distal myopathy families and de novo in one Finnish patient.

Dubourg O, Maisonobe T, Behin A, Suominen T, Raheem O, Penttilä S, Parton M, Eymard B, Dahl A, Udd B.

J Neurol. 2011 Jun;258(6):1157-63. doi: 10.1007/s00415-011-5900-9. Epub 2011 Jan 30.

PMID:
21279644
40.

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.

Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC.

Clin Cancer Res. 2010 Dec 15;16(24):6159-68. doi: 10.1158/1078-0432.CCR-10-1027. Epub 2010 Aug 27.

41.

Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008.

Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG.

Neuromuscul Disord. 2010 Feb;20(2):142-7. doi: 10.1016/j.nmd.2009.11.003. Epub 2010 Jan 13. No abstract available.

PMID:
20074951
42.

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2010 Jan;119(2):315-23. doi: 10.1007/s10549-009-0329-x. Epub 2009 Feb 27.

PMID:
19247830
43.

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.

Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2009 Jul;116(1):53-68. doi: 10.1007/s10549-008-0081-7. Epub 2008 Jul 1.

PMID:
18592370
44.

WITHDRAWN: Amino acids for amyotrophic lateral sclerosis / motor neuron disease.

Parton M, Mitsumoto H, Leigh PN.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003457. doi: 10.1002/14651858.CD003457.pub2. Review.

PMID:
18425887
45.

Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.

Parton M, Smith IE.

J Clin Oncol. 2008 Feb 10;26(5):745-52. doi: 10.1200/JCO.2007.14.3016. Review. No abstract available.

PMID:
18258982
46.

Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.

Parton M, Gore M, Eisen T.

J Clin Oncol. 2006 Dec 10;24(35):5584-92. Review.

PMID:
17158544
47.

No association of the SOD1 locus and disease susceptibility or phenotype in sporadic ALS.

Broom WJ, Parton MJ, Vance CA, Russ C, Andersen PM, Hansen V, Leigh PN, Powell JF, Al-Chalabi A, Shaw CE.

Neurology. 2004 Dec 28;63(12):2419-22.

PMID:
15623718
48.

High incidence of HER-2 positivity in inflammatory breast cancer.

Parton M, Dowsett M, Ashley S, Hills M, Lowe F, Smith IE.

Breast. 2004 Apr;13(2):97-103.

PMID:
15019688
49.

Amino acids for amyotrophic lateral sclerosis / motor neuron disease.

Parton M, Mitsumoto H, Leigh PN.

Cochrane Database Syst Rev. 2003;(4):CD003457. Review. Update in: Cochrane Database Syst Rev. 2008;(2):CD003457.

PMID:
14583978
50.

Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells.

Zabaglo L, Ormerod MG, Parton M, Ring A, Smith IE, Dowsett M.

Cytometry A. 2003 Oct;55(2):102-8.

Supplemental Content

Loading ...
Support Center